Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
An Umbrella Review on Treatments and Therapeutic Options for Covid-19; [«Зонтичный» Обзор Средств И Стратегий Лечения При Covid-19] Publisher



Alinaghi SS1 ; Afsahi AM2 ; Molla A3 ; Mirzapour P4 ; Shahidi R3 ; Siami H5 ; Rad FF6 ; Abbaspour F6 ; Mozafari N3 ; Fakhredini K7 ; Mehraeen E8 ; Dadras O9
Authors
Show Affiliations
Authors Affiliations
  1. 1. Research Center for HIV/AIDS (IRCHA), Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Radiology, School of Medicine, University of California, San Diego (UCSD), CA, United States
  3. 3. School of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran
  4. 4. Iranian Research Center for HIV/AIDS (IRCHA), Tehran University of Medical Sciences, Tehran, Iran
  5. 5. School of Medicine, Islamic Azad University, Tehran, Iran
  6. 6. School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  7. 7. Behavioral Diseases Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
  8. 8. Department of Health Information Technology, Khalkhal University of Medical Sciences, Khalkhal, Iran
  9. 9. Department of Addiction Medicine, Haukland University Hospital, Bergen, Norway

Source: Russian Journal of Infection and Immunity Published:2023


Abstract

Introduction. As the COVID-19 pandemic continues to pose a significant challenge to global health, effective therapeutic options for preventing and treating the disease have become increasingly important. We aimed to provide an update on current treatments and therapeutic options for COVID-19 patients. Materials and methods. The purpose of this umbrella review is to explore the current treatments and therapeutic options for COVID-19 patients. Keywords and their combinations were searched across online databases in Embase, PubMed/MEDLINE, Web of Science, and Scopus spanning from July 1, 2020, through March 3, 2023. Publications were selected for data extraction in two steps based on the study inclusion/exclusion criteria. The study adheres to the PRISMA checklist as well as NIH bias risk and quality assessment tool. Results. In this review, 28 relevant articles were selected for the final qualitative synthesis. The majority of included studies had reported on the efficacy of Lopinavir/Ritonavir (n = 4), Ivermectin (n = 3), Baricitinib (n = 2), Tocilizumab (n = 2), Remdesivir (n = 2), ACEI/ARB (n = 2), Vitamin D (n = 2), Molnupiravir (n = 2), Traditional Chinese medicine (TCM) (n = 2), Convalescent plasma transfusion (CPT) (n = 2) and hydroxychloroquine (n = 2) in treating COVID-19. It appeared that Baricitinib, Remdesivir, ACEI/ARB, TCM, and CPT may have beneficial effects on reducing mortality, hospitalization duration, and disease severity in COVID-19 patients. Other interventions, such as Lopinavir/Ritonavir, Ivermectin, Vitamin D, and Hydroxychloroquine did not show clear benefits or had inconclusive results. Conclusion. This umbrella review provides a comprehensive overview of the current evidence on the effectiveness and safety of various pharmacological and non-pharmacological interventions for COVID-19. These results provide an updated overview of the current landscape for COVID-19 treatments, highlighting potential avenues for further research and clinical practice. It is crucial to continue monitoring emerging evidence and conducting rigorous studies to guide the development and optimization of therapeutic strategies against COVID-19. © 2023 Saint Petersburg Pasteur Institute. All rights reserved.
Related Docs
Experts (# of related papers)